Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1181 | Thyroid 3 | ECE2019

Ethanol ablation of cystic thyroid nodules: an effective and not aggressive treatment

Hernando Inigo , Cuesta Julian , Mingo Alberto , Jimenez Sara , Marazuela Monica , Sampedro-Nunez Miguel Antonio , Lahera Marcos

Introduction: Simple aspiration is the first-line treatment used for benign cystic thyroid nodules. However, a high recurrence rate has been reported with this procedure. When this happens, percutaneous ethanol injection into the nodules has proven to be an effective technique which can reach a volume reduction of about 85% (Kim et al., Eur Radiol. 2012 Jul;22(7):1573–8).Material and methods: Descriptive analysis of percutaneous 96° et...

ea0049ep1481 | Thyroid (non-cancer) | ECE2017

Lymph node categorization as a prognostic factor in a historical series of medullary thyroid cancer cases within a regional hospital

Moreno Nerea Aguirre , Gonzalez Elena Fernandez , Mena Sandra Campos , Azpiroz Monica Marazuela , Vargas Marcos Lahera

Introduction: Medullary thyroid cancer (MTC) TNM classification categorizes lymph nodes (LN) according to their location, but does not consider number and size of LN.Objective: To analyze the relationship between number and size of LN in MCT persistent disease (PD).Material and methods: Retrospective study of patients with MTC followed up in a regional hospital from 1985 to 2015. The main variables (expressed as qualitative in freq...

ea0056p1192 | Thyroid cancer | ECE2018

Tyrosine kinase inhibitors in iodine-refractory thyroid cancer. Clinical experience

Marijuan Clara , Pla Begona , Aguirre Nerea , Fernandez Elena , Hernando Inigo , Jimenez Sara , Marazuela Monica , Lahera Marcos

Introduction: Tyrosine kinase inhibitors (TKIs) are used for treatment of iodine-refractory differentiated thyroid cancer (DTC) in patients with progressive advanced disease.Sorafenib and lenvatinib are the TKIs currently approved for this indication.Objective: To describe the clinical experience in patients with iodine-refractory DTC treated with TKIs in our Institution.Materials and methods: Restrospective cohort study of patient...

ea0063p1216 | Thyroid 3 | ECE2019

Real-life experience with lenvatinib in iodine-refractory thyroid cancer in a terciary hospital

Sanchez Clara Marijuan , Peris Begona Pla , Moreno Nerea Aguirre , Alday Inigo Hernando , Blanco Sara Jimenez , Azpiroz Monica Marazuela , Vargas Marcos Lahera

Introduction: Lenvatinib is an oral tyrosine kinase inhibitor (TKI) used for treatment of progressive, clinically significant or symptomatic disease in patients with iodine-refractory differentiated thyroid cancer (DTC).Objective: To describe our clinical experience with lenvatinib in patients with iodine-refractory differentiated thyroid cancer.Methods: Restrospective cohort study of patients with iodine-refractory differentiated ...

ea0070aep327 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Metabolic effects of semaglutide after the first months of treatment: A new GLP-1-RA revolution?

Jiménez Sara , Pla Begoña , M Ramos-Leví Ana , Carraro Raffaele , Lahera Marcos , Hernando Iñigo , Alfonso Arranz J , Marazuela Mónica

Background: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1-RA) whose role as a second-line treatment for patients with type 2 diabetes (T2D) has significantly increased. It has demonstrated cardiovascular safety and superiority in terms of glycaemic control and weight loss, compared to other GLP-1-RAs. The most common side effects are mild gastrointestinal, but it may also cause renal failure secondary to dehydration and an increased risk of diabetic retinopa...

ea0056p740 | Growth hormone IGF axis - basic | ECE2018

GH replacement therapy (GHRT) in adult patients with GH deficiency (GHD): a long term follow up

Peris Begona Pla , Ramos-Levi Ana Maria , Marijuan Clara , Fernandez Elena , Aguirre Nerea , Mosse Alexia , Jimenez Sara , Hernando Inigo , Vargas Marcos Lahera , Azpiroz Monica Marazuela

Introduction: GH deficiency (GHD) leads to altered body composition, lipid metabolism and quality of life, and is also associated to an increased cardiovascular morbidity and mortality. The aim of this study was to evaluate long-term changes after treatment with GH replacement therapy (GHRT).Methods: We retrospectively reviewed adult patients with GHD in our clinic who were treated with GHRT. We evaluated demographic (etiology, age, dose), anthropometric...

ea0056p1166 | Thyroid cancer | ECE2018

Descriptive analysis of papillary thyroid microcarcinomas in a single-center

Gonzalez Elena Fernandez , Moreno Isabel Huguet , Munoz Jose Luis , Moreno Nerea Aguirre , Peris Begona Pla , Sanchez Clara Marijuan , Castro Marta Araujo , Ramos-Levi Ana , Azpiroz Monica Marazuela , Ramirez Manuel Luque , Vargas Marcos Lahera

Introduction: The incidence of papillary thyroid microcarcinomas (MPT, max diameter≤10 mm) has increased in recent years. Most have a very good prognosis but some have growth during follow-up, lymph node and / or distant metastases.Material and methods: We performed a single-center, retrospective cohort study, n=114 patients (86% women, average age 48.3 years), diagnosed with MPT between 1998 and 2012. Risk stratification system (ATA 2015): 10 high...